Drawing for LONTOR

USPTO serial 87404870

LONTOR

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
MAYER, DAVID COREY
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LONTOR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

MAURY M. TEPPER, III TEPPER & EYSTER, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; Pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; Pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; Pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of kidney diseases; Pharmaceutical preparations for the prevention and treatment of diabetes; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer and tumors; Pharmaceutical preparations for the prevention and treatment of allergies; Pharmaceutical products for the prevention and treatment of bone diseases; Pharmaceutical products for the prevention and treatment of respiratory diseases and asthmaACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 7, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 7, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 5, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 8, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 8, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 19, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 13, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
May 10, 2018RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 27, 2017RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 27, 2017GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 27, 2017GNSLLETTER OF SUSPENSION E-MAILED
Apr 27, 2017CNSLSUSPENSION LETTER WRITTEN
Apr 27, 2017DOCKASSIGNED TO EXAMINER
Apr 15, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 13, 2017NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance